A Sign of the Times: Chi-Med's MediPharma Steps Toward Independence
This article was originally published in Start Up
In order to unlock what it considers unrecognized value in its R&D group, Hutchison China MediTech has taken the first steps toward spinning out Medipharma by instituting a new employee option scheme and incentivization program. This story also appeared this month in PharmAsia News.
You may also be interested in...
WuXi PharmaTech's spectacular public offering last summer piqued foreign investors' interest. Top tier VC firms are now investing in contract research organizations, manufacturing plays, and start-ups shifting business operations to China.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.